Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
CorMedix stock price drops 5% due to Q4 earnings falling short of expectations
New Jersey Parsippany - On Thursday, CorMedix Inc. (NASDAQ: CRMD) announced its Q4 earnings, which fell short of profit expectations despite meeting revenue targets.
The company’s stock dropped 5.34% in pre-market trading.
The biopharmaceutical company’s adjusted earnings per share for the quarter were $0.16, significantly below the analyst consensus of $0.85.
Revenue reached $128.6 million, slightly above the expected $128.48 million, representing a substantial increase from $31.2 million in the same period last year.
The 312% year-over-year revenue growth was primarily driven by DefenCath sales of $91.2 million and Melinta product portfolio sales of $37.4 million, following the company’s acquisition of Melinta in August 2025.
For the full year 2025, CorMedix reported a net profit of $163.0 million, or $2.04 per diluted share, compared to a net loss of $17.9 million in 2024.
Total annual revenue reached $311.7 million, with projected full-year revenue including Melinta’s performance at $401.3 million.
Chairman and CEO Joe Todisco stated, “I am proud of the progress we made over the past year. We accelerated patient access to DefenCath, completed the acquisition and integration of Melinta, and made progress in two ongoing Phase 3 clinical trials.”
Total operating expenses for Q4 were $48.2 million, up 182% from $17.1 million in the same period last year, mainly due to the Melinta acquisition.
The quarter included $4.1 million in one-time integration-related costs. Adjusted EBITDA for Q4 was $77.2 million, compared to $15.3 million in the same period last year.
CorMedix reaffirmed its 2026 guidance, expecting net revenue between $300 million and $320 million, with a midpoint of $310 million, and adjusted EBITDA between $100 million and $125 million. The company expects to release Phase 3 ReSPECT study data for REZZAYO in Q2 2026.
This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.